BIA-ALCL

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) understandably worries patients, but it is important to understand exactly what it is — and what it is not. BIA-ALCL is not a breast cancer. It is a rare type of lymphoma, a cancer of the immune system, that develops in the fluid and scar capsule surrounding a breast implant. It is rare, it is strongly associated with particular implant surfaces, and — crucially — when detected early it is usually very treatable.

What we know about the cause

BIA-ALCL has been linked predominantly to textured implants, and the risk appears to rise with the roughness and surface area of the texture. The risk associated with smooth implants appears very low, and reported cases in patients who have only ever had smooth implants are exceptionally rare. The exact mechanism is not fully established, but theories centre on chronic inflammation, the implant surface and possibly bacterial biofilm. Because of the association, some macro-textured products have been withdrawn internationally, and the use of textured implants has declined.

The UK picture

The MHRA monitors BIA-ALCL through the national implant registry and adverse-incident reporting. UK case numbers are tracked and the reported rate is low relative to the number of implants used. The MHRA, together with a plastic surgery expert advisory group, has published UK guidelines on diagnosis and treatment. The overall message from regulators is consistent: the condition is rare, awareness of the warning signs is important, and routine removal of implants purely as a precaution is not recommended in people without symptoms.

Warning signs to know

The most common presentation is new swelling of one breast, typically occurring some years after surgery, caused by a build-up of fluid (a seroma) around the implant. Other possible signs include a lump in the breast or armpit, pain, or a change in the skin or breast shape. Because these symptoms usually appear late — often several years or more after implantation — any new, unexplained, one-sided swelling in someone with implants should be investigated promptly.

How it is diagnosed and treated

If BIA-ALCL is suspected, investigation typically involves an ultrasound and sampling of the fluid around the implant for specialist laboratory testing (including a marker called CD30). If confirmed, treatment in most early cases involves surgery to remove the implant together with the surrounding capsule (en bloc capsulectomy). For disease caught at this early stage, the outlook is generally very good, and many patients need no further treatment. More advanced cases may require additional treatment under the care of a specialist team.

What this means if you have implants

• If you have no symptoms: routine removal of textured implants is not recommended. Be aware of the warning signs and seek review if they appear.
• Know your implants: ask your surgeon whether your implants are smooth or textured, and keep your implant card and details.
• If you notice late swelling, a lump or pain: see your GP or surgeon promptly for assessment — do not wait.
• If you are choosing implants now: discuss surface type and the current evidence with your surgeon as part of your decision.

This is understandably a sensitive subject. If you are worried about symptoms, speak to your GP or surgeon, who can arrange appropriate assessment.

Frequently asked questions